BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to determine the effect of BI 17444Cl on the lung
function over a 24-hour period, when it is inhaled using the Respimat inhaler in patients
with chronic obstructive pulmonary disease. In the trial four treatments of each 3 weeks of
duration are included: 2 dosages in a once daily administration and 2 dosages for
administration twice daily.